Molecular Classification of Endometrial Cancer: Impact on Adjuvant Treatment Planning.

Molecular classification that has been recently incorporated in FIGO classification of endometrial cancer is a new triage tool for the better management of endometrial cancer patients.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Endometrial Cancer Endometrial Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Neoplasms Neoplasms by Site Urogenital Diseases Urogenital Neoplasms Uterine Diseases Uterine Neoplasms

Age range

18 year–80 year

Sex eligibility

Female

Study type

Observational

Primary location

1st Department of Obstetrics & Gynecology, AUTh, "Papageorgiou" Hospital

Thessaloniki, Greece

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Histological confirmation of endometrial cancer.
Surgical treatment at our Gynecological - Oncology Unit.

Exclusion criteria

Refusal to be tested for the molecular classification
Presence of a synchronous neoplasm.

Treatment and study plan

Primary outcomes

Multidisciplinary Team Board decision change

Time frame: 2 years (study completion)

MDT decision for adjuvant treatment (Rate of adjuvant treatment change)

Sponsors and collaborators

Lead sponsor

Aristotle University Of Thessaloniki

Other

Registry information

Important dates

Study start: 2022
Primary completion: 2024
Study completion: 2025
First posted: Sep 5, 2024
Registry last updated: Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting